Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Medulloblastoma 2Glioblastoma 2Ependymoma 2Brain Neoplasms 2Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Diffuse Intrinsic Pontine Glioma 1Adenocarcinoma 1

Interventions

pembrolizumab 91Blood Specimen Collection 44Cyclophosphamide 37Nivolumab 36Bevacizumab 36Standard of Care 32Carboplatin 31Surveys and Questionnaires 29Paclitaxel 28atezolizumab 25Exercise 25Pemetrexed 24Gemcitabine 24Cisplatin 23Fluorouracil 22Radiotherapy 20Leucovorin 20Dexamethasone 20Oxaliplatin 19Docetaxel 19Rituximab 16Irinotecan 16Cetuximab 16dostarlimab 15Drug Therapy 15Doxorubicin 15Biopsy 15130-nm albumin-bound paclitaxel 15Prednisone 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × 1-methyltryptophan × 1 year × Clear all
NCT02077881 2026-04-03

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Lumos Pharma

Phase 1/2 Completed
157 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡